In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
ANGLE and Abbott seek blood test for metastatic breast cancer
Dana-Farber/Brigham and Women’s team identifies set of seven microRNAs that could detect early-stage ovarian cancer
Companies to evaluate novel bispecific agents combining anticalin technology with select antibodies
New discoveries in cancer-related targets and pathways, plus other recent news in oncology R&D and clinical trials
Immutep and Merck ink a collaborative clinical trial deal to test IMP321 and Keytruda in multiple cancer types
BioLineRx’s BL-8040 and AGI-134 programs boost survival in preclinical studies
Rexahn announces collaboration with Zhejiang Haichang Biotechnology for development of Archexin to treat hepatocellular carcinoma
CIRM awards $4M to Fate Therapeutics to support a first-in-human trial of FT516
(Photo credit: NCI, NIH)
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
by Dr. Eyal Talor, CEL-SCI
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies

by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.